Detalles de la búsqueda
1.
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Blood
; 142(1): 73-89, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018663
2.
Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis.
J Allergy Clin Immunol
; 152(1): 205-213, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36813186
3.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol
; 193(5): 915-921, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782950
4.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34418168
5.
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Eur J Haematol
; 98(1): 57-66, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428357
6.
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Ther Drug Monit
; 38(2): 230-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26693810
7.
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Eur J Haematol
; 94(3): 243-50, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25082346
8.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 781-787, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38278960
9.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
J Clin Invest
; 132(17)2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047494
10.
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Leuk Res
; 90: 106310, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32058176
11.
Intestinal flora in very low-birth weight infants.
Acta Paediatr
; 98(11): 1762-7, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19673724
12.
Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
EBioMedicine
; 43: 150-158, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975542
13.
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Oncoimmunology
; 8(9): e1638210, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31428530
14.
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 925, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38418611
15.
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
Leuk Res
; 50: 95-103, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27710869
16.
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Leukemia
; 35(8): 2416-2418, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33589755
17.
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Mol Cancer Ther
; 14(5): 1181-91, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25761894
18.
Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
PLoS One
; 8(1): e55818, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23383287
19.
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
J Clin Oncol
; 32(25): 2821-3, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25071107
Resultados
1 -
19
de 19
1
Próxima >
>>